Share the article

Understand  –  Why should I care?

Carriage of resistant bacteria

Antibiotic treatment is associated with a risk to become a carrier and for suffering future infection with resistant bacteria.

Selection of antibiotic resistant bacteria in the microbiome

Any bacterium has the potential to evolve resistance. When you take an antibiotic, not only the infecting bacteria but also bacteria normally living in the body, the microbiome, will be reduced in numbers (for more on the microbiome, see Bacteria – Essential for human life). This leaves an open space and an opportunity for resistant bacteria to proliferate. Sometimes the resistant bacteria become established in the normal flora, and may prevail in the body for many years after ending the treatment (reviewed in).

This can become a problem later in life; such bacteria may cause a serious and hard to treat infection in the future. Further, the resistance mechanisms may spread to other bacteria and the resistant bacteria may spread to people in your family and in the community. Suboptimal dosing, long duration of treatment and use of broad-spectrum antibiotics increases the risk for selection of resistant bacterial clones. Carriage can also be the result of exposure to for example food or environmental sources contaminated with resistant bacteria.

Colonization and future infection with resistant bacteria, examples:

  • Exposure to antibiotics is followed by increased risk for colonization with resistant bacteria for several years, probably due to selection of resistant clones in the normal flora.
  • Use of certain antibiotics in the preceding 1-2 months increased the risk 2-5 fold for nasal carriage of penicillin-resistant pneumococci among children. Also siblings to treated children had an increased risk for carriage, indicating spread within families .
  • Exposure to antibiotics in the 3-month period before a community-acquired urinary tract infection was found to be a risk factor for infection with multidrug-resistant ESBL (extended-spectrum beta-lactamase)-producing E. coli.
  • Prior use of antibiotics was also found to increase the risk for bloodstream infection (sepsis) with resistant Gram-negative bacteria .
  • Athletes have been found to be at higher risk for becoming carriers of MRSA (methicillin-resistant Staphylococcus aureus). Importantly, being a carrier was associated with a 7-fold higher risk of developing MRSA infection.
  • Antibiotic resistance spreads silently across the world. More than 60% of the populations in some areas carry multidrug-resistant bacteria as part of their normal bacterial flora. The exact routes of spread are not clear, but environmental contamination likely contributes.

Selected Resources

Resource Description
The rise in antibiotic resistance Animation of selection of resistant bacteria in the body, some resistance mechanisms and how they may spread.
1.
Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest [Internet]. 2014 Oct;124(10):4212–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25271726
1.
Stewardson AJ, Huttner B, Harbarth S. At least it won’t hurt: the personal risks of antibiotic exposure. Curr Opin Pharmacol [Internet]. 2011 Oct;11(5):446–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21775205
1.
Nasrin D, Collignon PJ, Roberts L, Wilson EJ, Pilotto LS, Douglas RM. Effect of beta lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ [Internet]. 2002 Jan 5;324(7328):28–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11777803
1.
Sjölund M, Tano E, Blaser MJ, Andersson DI, Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerging Infect Dis [Internet]. 2005 Sep;11(9):1389–93. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310621/
1.
Karanika S, Kinamon T, Grigoras C, Mylonakis E. Colonization with Methicillin-Resistant Staphylococcus aureus and Risk for Infection among Asymptomatic Athletes: A Systematic Review and Meta-Analysis. Clin Infect Dis [Internet]. 2016 Apr 18 [cited 2016 Apr 25];ciw240. Available from: http://cid.oxfordjournals.org/content/early/2016/04/17/cid.ciw240
1.
Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M de, Gálvez J, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect [Internet]. 2008 Feb;14(2):180–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18005358
1.
Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis [Internet]. 2004 Mar;23(3):163–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14986159
1.
Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med [Internet]. 2003 Sep 16;139(6):483–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13679325
1.
Woerther P-L, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev [Internet]. 2013 Oct;26(4):744–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24092853
1.
Samore MH, Lipsitch M, Alder SC, Haddadin B, Stoddard G, Williamson J, et al. Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol [Internet]. 2006 Jan 15;163(2):160–70. Available from: aje.oxfordjournals.org/content/163/2/160.long
1.
Sumanas, Inc., Sinauer Associates, Inc., W. W. Norton & Company, Inc. The Rise in Antibiotic Resistance [Internet]. Sumanas, Inc. Multimedia Development Services. 2002 [cited 2015 Jan 26]. Available from: http://www.sumanasinc.com/scienceinfocus/sif_antibiotics.html